tiprankstipranks
Trending News
More News >
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
US Market

Y-Mabs Therapeutics (YMAB) Stock Statistics & Valuation Metrics

Compare
516 Followers

Total Valuation

Y-Mabs Therapeutics has a market cap or net worth of $238.64M. The enterprise value is $109.71M.
Market Cap$238.64M
Enterprise Value$109.71M

Share Statistics

Y-Mabs Therapeutics has 45,283,676 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,283,676
Owned by Insiders17.07%
Owned by Institutions36.10%

Financial Efficiency

Y-Mabs Therapeutics’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -32.06%.
Return on Equity (ROE)-0.32
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)-32.06%
Return on Capital Employed (ROCE)-0.32
Revenue Per Employee843.13K
Profits Per Employee-285.25K
Employee Count104
Asset Turnover0.73
Inventory Turnover2.11

Valuation Ratios

The current PE Ratio of Y-Mabs Therapeutics is -11.70. Y-Mabs Therapeutics’s PEG ratio is 0.24.
PE Ratio-11.70
PS Ratio0.00
PB Ratio1.90
Price to Fair Value3.77
Price to FCF-11.21
Price to Operating Cash Flow-11.11
PEG Ratio0.24

Income Statement

In the last 12 months, Y-Mabs Therapeutics had revenue of 87.69M and earned -29.67M in profits. Earnings per share was -0.67.
Revenue87.69M
Gross Profit72.43M
Operating Income-31.20M
Pretax Income-29.81M
Net Income-29.67M
EBITDA-30.67M
Earnings Per Share (EPS)-0.67

Cash Flow

In the last 12 months, operating cash flow was -15.71M and capital expenditures 0.00, giving a free cash flow of -15.71M billion.
Operating Cash Flow-15.71M
Free Cash Flow-15.71M
Free Cash Flow per Share-0.35

Dividends & Yields

Y-Mabs Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.93
52-Week Price Change-56.34%
50-Day Moving Average4.42
200-Day Moving Average8.66
Relative Strength Index (RSI)68.01
Average Volume (3m)198.32K

Important Dates

Y-Mabs Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date

Financial Position

Y-Mabs Therapeutics as a current ratio of 4.16, with Debt / Equity ratio of 0.89%
Current Ratio4.16
Quick Ratio3.85
Debt to Market Cap<0.01
Net Debt to EBITDA2.17
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Y-Mabs Therapeutics has paid -146.00K in taxes.
Income Tax-146.00K
Effective Tax Rate<0.01

Enterprise Valuation

Y-Mabs Therapeutics EV to EBITDA ratio is -9.15, with an EV/FCF ratio of -17.86.
EV to Sales3.20
EV to EBITDA-9.15
EV to Free Cash Flow-17.86
EV to Operating Cash Flow-17.86

Balance Sheet

Y-Mabs Therapeutics has $67.23M in cash and marketable securities with $820.00K in debt, giving a net cash position of -$66.41M billion.
Cash & Marketable Securities$67.23M
Total Debt$820.00K
Net Cash-$66.41M
Net Cash Per Share-$1.47
Tangible Book Value Per Share$2.02

Margins

Gross margin is 82.61%, with operating margin of -35.58%, and net profit margin of -33.83%.
Gross Margin82.61%
Operating Margin-35.58%
Pretax Margin-34.00%
Net Profit Margin-33.83%
EBITDA Margin-34.97%
EBIT Margin-35.58%

Analyst Forecast

The average price target for Y-Mabs Therapeutics is $13.86, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$13.86
Price Target Upside163.00% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast3.38%
EPS Growth Forecast-36.40%

Scores

Smart Score4
AI Score44
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis